Operating Income (Loss) in USD of Greenwich LifeSciences, Inc. from Q3 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Greenwich LifeSciences, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2019 to Q3 2025.
  • Greenwich LifeSciences, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$4.17M, a 53% decline year-over-year.
  • Greenwich LifeSciences, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$19.6M, a 82% decline year-over-year.
  • Greenwich LifeSciences, Inc. annual Operating Income (Loss) for 2024 was -$16M, a 71.7% decline from 2023.
  • Greenwich LifeSciences, Inc. annual Operating Income (Loss) for 2023 was -$9.33M, a 16% decline from 2022.
  • Greenwich LifeSciences, Inc. annual Operating Income (Loss) for 2022 was -$8.04M, a 74.9% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Greenwich LifeSciences, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$19.6M -$4.17M -$1.45M -53% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-14
Q2 2025 -$18.1M -$4.05M -$1.38M -52% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 -$16.8M -$3.28M -$745K -29.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-20
Q4 2024 -$16M -$8.08M -$5.25M -185% Oct 1, 2024 Dec 31, 2024 10-K 2025-04-15
Q3 2024 -$10.8M -$2.73M -$226K -9.03% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-14
Q2 2024 -$10.5M -$2.66M -$914K -52.3% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 -$9.62M -$2.54M -$296K -13.2% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-20
Q4 2023 -$9.33M -$2.84M +$58.7K +2.03% Oct 1, 2023 Dec 31, 2023 10-K 2025-04-15
Q3 2023 -$9.39M -$2.5M -$120K -5.03% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$9.27M -$1.75M -$975K -126% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$8.29M -$2.24M -$252K -12.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-20
Q4 2022 -$8.04M -$2.89M -$517K -21.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 -$7.52M -$2.38M -$1.52M -175% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-19
Q2 2022 -$6.01M -$773K -$19.9K -2.64% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-21
Q1 2022 -$5.99M -$1.99M -$1.39M -231% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-22
Q4 2021 -$4.6M -$2.38M -$1.23M -106% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$3.37M -$867K -$610K -237% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$2.76M -$753K -$543K -258% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$2.22M -$601K -$356K -146% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-20
Q4 2020 -$1.86M -$1.15M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 -$257K +$79.1K +23.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$210K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$245K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-20
Q3 2019 -$336K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16

Greenwich LifeSciences, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$16M -$6.68M -71.7% Jan 1, 2024 Dec 31, 2024 10-K 2025-04-15
2023 -$9.33M -$1.29M -16% Jan 1, 2023 Dec 31, 2023 10-K 2025-04-15
2022 -$8.04M -$3.44M -74.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-04-15
2021 -$4.6M -$2.73M -147% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 -$1.86M +$1.56M +45.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-21
2019 -$3.43M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.